Welcome to the Royal Philips Electronics First Quarter Results 2012 Conference Call on Monday, 23rd of April 2012. During the introduction hosted by Mr. Frans van Houten, CEO; and Mr. Ron Wirahadiraksa, CFO, all participants will be in a listen-only mode. After the introduction, there will be an opportunity to ask questions. (Operator Instructions). Please note that this call will be recorded and is available by webcast on the website of Royal Philips Electronics. I will now hand the conference over to Mr. Abhijit Bhattacharya, Head of Investor Relations. Please go ahead, sir.

Good morning, ladies and gentlemen. Welcome to this conference call on the first quarter of 2012 for Royal Philips Electronics. I am here with the Philips’ CEO, Mr. Frans van Houten; and our CFO, Ron Wirahadiraksa. In a moment, Frans will take you through his introductory remarks and provide an update on our performance. Ron will shed more light on the details of the financial performance during the quarter. After this, both Frans and Ron will be happy to take your questions. As usual, our press release and the accompanying information slide deck were published at 7 AM Central European Time this morning. Both documents are now available for download from our Investor Relations website. We will also make available a full transcript of this conference call on the Investor Relations website by tomorrow at the latest. With that, let me hand over to Frans to start proceedings for the day.

Thanks, Abhijit. Welcome and thank you for joining us today for our first quarter 2012 earnings conference call. The end of the first quarter marks the completion of my first year as CEO of Philips. And as I reflect on my tenure this far, I am pleased with the progress that we have made over the last year. It remains clear that Philips has a wealth of talent, great assets, a strong brand, a global footprint, we operate in the right markets and have the right portfolio to address key global trends, and a large majority of our businesses have the right fundamentals for profitable growth. Yet, our performance does not match our potential. In order to address this disparity, we designed and launched our change in improvement program Accelerate! which is aimed at reigniting organic growth in Philips, and making us an agile entrepreneurial innovator. I’m happy to report that we are now seeing solid improvement across all sectors of our business and our growth figures for the first quarter confirm this trend, with Healthcare growing at 9%, Consumer Lifestyle growth businesses above 7%, and Lighting at 2%. Excluding external sales of Lumileds, which saw a double-digit decline in the quarter, due to inventory correction in the channel and an increasing mix of internal sales, our Lighting business actually grew by 4% in the quarter. LED product sales for the quarter grew by 22%, and if we were to exclude Lumileds even by 50%. As one of the work streams within the Accelerate! program we are reducing the overhead cost structure of the company and we made good progress and are on track with these plans. In the first quarter of this year, we reduced cost by about EUR37 million and that is on top of the EUR25 million…

Thank you, Frans. Good morning and welcome to all of you on the call. I will begin by giving you some color on the developments in the markets we serve, and then walk you through the financial performance for the first quarter. So let me start with Healthcare, where in US, we see the outlook as a positive, although the industry will have to deal with the prevailing uncertainties regarding the healthcare reform and possible impacts of the medical devices excise tax. A vast majority of hospital executives expect increases in overall spending budget this year, marking a significant improvement compared to just two years ago. Continued low interest rates are fueling these infrastructure advancements in addition to continued strong IT spending in hospitals. In Europe, the outlook for market in Southern Europe continued to be weak and there is a rather subdued out of economic growth for the remaining part of Europe. The austerity measures undertaken in countries such as Italy, Spain and Greece, significantly affect public spending on Healthcare. We, therefore, remain cautious on the near-term outlook in the region. That said, the momentum in our growth geographies continued well into the first quarter of 2012, where demand is fuelled by government and private spending. On consumer markets, US consumer confidence continued to improve from its low point in Q3 2011 and is not slightly above levels of a year-ago. Unemployment continued to fall to a levels now just above 8% in March. Private consumption, however, remains somewhat subdued. In Europe, consumer confidence in Germany and France remained more or less stable compared to Q1, with levels still below those of last year. Unemployment in Germany has continued to fall and is now under 7% in March. In France, however, unemployment has crept up again to a level…

Thank you, sir. (Operator Instructions). The first question comes from Andreas Willi from JP Morgan. Please proceed with your question. Andreas Willi – JP Morgan: Good morning, gentlemen. I have a – my first question is on the Healthcare business. Even if you take into account the push outs which you quantified in the call, it still seems a very strong underlying result in terms of sales growth. Should we expect that pace to be maintained in the near quarters? And also given that strong sales growth, isn’t the profitability still somewhat disappointing also in the year-on-year comparison? That’s the first question. And the second question on the old Consumer Electronics business, maybe you can say how big that by now still is in terms of sales and whether the faster decline in some of the DVD players optical pickup we should also expect licensing income to fall faster than you previously indicated.

Okay Andreas, thanks for these three questions. Let’s first talk a bit about Healthcare and then maybe Ron can also contribute with some more color. So yes, we believe we have a strong position in Healthcare and that’s on the back of a strong product range and investments in innovation, where we can also see that during 2011 we have actually gained market share. With the overall order intake in Healthcare at around 7% and especially very strong in the growth markets, we are obviously pleased with a strengthened order book where we take courage them for the future. And so we hope to continue good momentum in the Healthcare business even though and we flagged that, the overall uncertainty in the market remains. With regard to your implied message that the profitability is not good enough, actually we would agree with you that Healthcare on its path to value to the midterm targets still has ways to go in improving profitability. And Healthcare will also benefit from the Accelerate! program in improving gross multiple in line and also the cost of reduction will benefit Healthcare. Deborah DiSanzo who is taking over on May 1 has already clearly signaled the wish to accelerate Healthcare further. So Lifestyle Entertainment, we saw a double-digit decline in Lifestyle Entertainment, despite that fact I said that the business continues to be profitable. I think this is exactly how we need to manage that business. We cannot help the fact that consumer buys fewer DVD players and Blu-Ray players, but we can manage the profitability. And as you know we have moved the units to Hong Kong, we have merged accessories and audio/video, we have taken lot of cost out, and then the net-net result is, is that despite a significantly lower sales the unit continues to be profitable. The proportion of Lifestyle Entertainment of the total of Philips – sorry, of CL, is approximately 30%. But that, of course, is coming down as we have the developments in Q1. And then with regard to licenses, I would like to lean on Ron, to give a good perspective on that.

Yes. So as we said the last year, we expect license income to come down in about three to four years time to a level of about 130 of income versus the 175 than it was last year. And that is as you rightfully say to indicate the decline in the optical licenses income. Of course, from 2013 onwards, we are expecting to receive the brand license from the TP Vision joint venture. A little color maybe, Frans, if you are okay on Healthcare. The answer is absolutely yes, spot on of course, but please bear in mind that we are at the run rate of expenses for our investments for growth in Healthcare that was slightly above Q1 2011 as we started with this in Q2, and we have had the conversation on that the last year. So other than that the impact of the sales that was brought back which we said in Q4 was a raise of 140 basis points is a little less now, because – the 130 basis points was a little bit less now, because not everything came back, but we are encouraged by what we see of what has comeback and that has not been a push-out to Q2. So that’s a little – more color on the Healthcare profitability. Andreas Willi – JP Morgan: Thank you very much.

Thank you. The next question comes from Simon Smith from Credit Suisse. Please proceed with your question. Simon Smith – Credit Suisse: Thank you. Yes, there were two topics that interested me. The first was with regard to Healthcare. And I mean we’ve obviously seen orders in Europe come down in the sort of a teens and obviously you’re down 1% in the quarter. You’ve – I guess you are implying that apart from Southern Europe, some of the other economies in Europe maybe sort of pulls more aggressively during the crisis and you’ve now started to see more normal order trend. I was wondering if you have given any greater detail on that. And I think as the other point is, is there has been a lot of discussion about how competition maybe developing in the Healthcare sector. And, I guess, Europe being the one area where we’re getting more clear weakness should be the one we would see it most. So just in terms of orders that are going on in Europe, as well as the actual volume of those orders, what are you seeing in terms of pricing, is there any acceleration of price weakness in any of those areas? And the second topic for me of interest was Lighting. And I mean obviously on Lighting, nice to see an improvement come through in profitability, and I guess we’ve seen a lot of pressure coming through from raw materials in that area. And I think pricing that’s been – you’ve had some successes in pricing and obviously hope to see more come through. And just wondered how much of that improvement is from pricing and what degree of price increases you further have to go through, how much of cost increases has not been recovered, and if you can give us any details on that?

Okay. Simon, hi, first of all let’s talk about Healthcare. You are right, we flag Europe to be – continue to be weak. We actually expect a mid single-digit decline in Healthcare in Europe. The order intake trend shows more benign development with the minus one in Q1 after several quarters of double-digit decline, but then that means that we have a significantly lower to our order book positioned there. So that’s then is filtered through in the mid single-digit decline in Healthcare for the – as an expectation. Competitive development, I’m not sure exactly what you are after there. We see that we can hold up our position well and with a strong panel of products both in the Imaging Diagnostics as well as in the Patient Monitoring and Home Healthcare. So we relate the European situation much more to the general economic situation rather than our competitive position. Then, let’s move to Lighting. Raw materials, we have tried very hard to bring that into the pricing. I think generally speaking we have succeeded, although in the consumer space, the consumer lamps area turned out to be quite hard. Especially in the area of CFL light, we saw that private label brands in the large retail stores were putting a hold to further price increases. And so I think we need to work on our internal fundamentals in Lighting. We’re taking significantly – significant cost out of that operation, anticipating that we cannot just count on gross margins to improve due to pricing. The good news is, is that we see a massive opportunity to improve the operational results in Lighting as we made the units more competitive. The – it’s also good to see that the LED’s business in the professional side we see good gross margins and also into the LED solution business we see healthy gross margins. So that also bodes well for the future mix. Simon Smith – Credit Suisse: Can I just follow-up on the Healthcare point?

Sure, go ahead. Simon Smith – Credit Suisse: Yes. I mean my question was more I mean in a very tough environment where there is a loss of – well there is three particularly strong competitors and there is a suggestion of new entrants, to keep winning orders in Europe and the orders you’re putting into the backlog, I mean are they going in the sort of similar margins to yield to what you are currently reporting or is there now maybe a greater element of discounting to win orders with some of these governments which are on the – a lot more pressure in terms of their budgets.

We have not seen an out of the order price erosion in the Healthcare market. So cannot acknowledge that. Simon Smith – Credit Suisse: Okay, thank you.

Thanks.

Thank you. The next question comes from Peter Reilly from Deutsche Bank. Please proceed with your question. Peter Reilly – Deutsche Bank: Good morning. You mentioned that you are still suffering from operational problems in the Lighting business, but in your own words, you have a handle on these. Can you give you us some more color on what the remaining operational problems are? And more importantly, when do you expect to be able say those problems are now behind us?

Well, it did well say that they are behind us. Peter Reilly – Deutsche Bank: I mean when will they be, because if you have a handle on them, then one would hope that there will be a stage later on this year when you can say they have now been resolved. And I was wondering when that is likely to be?

All right, let’s talk about the bigger picture in Lighting, all right. So we have had – we have seen seven quarters of declining performance and we are happy to see that the first quarter is a break in that trend. Nevertheless, the results in the first quarter, of course are not still not very good, they are just an improvement that’s all. The things that we are working on in Lighting are multifold. First of all, the turnaround of the Lumileds unit where we see margin pressure due to some oversupply in the market as well as operational issues. We’ve replaced the management team there, we are expecting improvements through the year and getting their unit back to the black figures. Number two is the Consumer Luminaire business, which is a self-inflicted issue with a supply chain that didn’t work very well and we are – we have now seen that that supply chain is back under control and we are working to restore the confidence of the customers, get their listings back in place, and that should result again more towards the end of the year for the unit to come back to the black. Then thirdly, as you recall, we have higher than normal investments in R&D and selling expenses especially on the professional solution side, the Professional Luminaires and the project business. As we see that as the future strategic hotspot of the business, in this area we actually see good growth. And I already referred to the fact that the underlying gross margins both at solutions business is actually healthy. So as we grow that business, we expect the profitability also there to improve. And then number four is the raw materials, which applies mainly to the lamps business, where we have been able to repair margins to a significant degree. And there probably most of the work on the margin improvement has been done, although on the cost side, we still can see many more opportunities to improve. So all-in-all, what I handover to Eric Rondolat is still a plateful of things to do, and over the next four quarters we need to see further margin improvement in Lighting. But I’m confident that from the low point where we come that we can achieve this. And we see that the competitiveness of the products and solutions – when you look for example of market shares that we are performing well. Peter Reilly – Deutsche Bank: And if I can just follow-up, when you say improvements over the next four quarters, I assume you’re building in into your analysis, an assessment of a continuing price declines in the LED business?

Well, the LED business, I mean the lamps of course have to come down, right? This is normal in a new technology. And at Light & Building in Frankfurt a week ago, I actually announced that we are launching LED lamps for the consumer market now for the first time below EUR10 to be launched first in Germany in April and rolled out over the rest of the European countries later this year. So we can do that because this is our a faster and new product introduction. Thanks to Accelerate! as a program, our unit is now – lamp business is now based in Shanghai and we are cranking our products every four to six months, so that goes well. Margin impression, I do not see that immediately in the professional side of the business. I’d like to underline that Lighting, for more than 70% it is B2B business and not a B2C business. Gross margins in the professional Lighting business are strong, and the payback time – thanks to energy efficiency, makes LED a very attractive proposition there already. So it’s a mouthful of insights, we are confident and positive on the overall potential of the Lighting business, while we still have quite a lot to do in the next 12 months. Peter Reilly – Deutsche Bank: Yes, thank you.

Thank you. The next question comes from Ben Uglow from Morgan Stanley. Please proceed with your question. Ben Uglow – Morgan Stanley: Good morning. I had a couple of questions. And on the Healthcare side, could you just give us a sense of what you think is driving the Patient Care business in particular? It’s obviously very decent growth. What I’m curious about is why Patient Care should be a double digit and Imaging Systems relatively flat. And I guess to sort of follow-up to that is, does your Patient Care business in principle carry similar margins to the remainder of your Healthcare business? So that was question number one. Number two is just a – is a clarification on Lighting. Quarter-on-quarter did you see slightly lower pressure – raw material pressure in the Lighting business. I know that you said that year-over-year things were still up, but I wondered if sequentially raw material pressures were diminishing slightly in Lighting.

Okay. Yes, good question. So the Patient Care business, let me elucidate first of all the strategy that we have there. So in Patient Care we are solutions provider, we help hospitals drive productivity in their patient care environment, so it’s no longer a product business. We are pretty strong in what we call Clinical Informatics and we link up all the boxes that help the nurses around the bed of the patient, we link them up to the central IT of the Intensive Care Unit and the hospital systems. By doing that it makes hospitals more productive, they can save on labor, nurses can help more patients. This is the competitive edge of Philips. As we glue all these things more together, we see that we have a very strong traction in gaining market share in what we call Patient Care & Clinical Informatics. The margins of PCCI are the best of all in Healthcare and also improving. So this is good news for Philips, Healthcare is – it in fact means a richer mix. In the Imaging area, I dare say that we still have some work to do to further improve the margin structure. As you recall, we are sitting not when we are building the sutural imaging operation, so that we can take better benefit from the supply chain in Asia and also being closer to that market. As we roll that out further and many products are expected to rollout into the market during 2012, we also hope to see margin expansion in the Imaging Systems area. Ron, anything to add on Healthcare?

Well, the PCCI margin is clearly above the average of Healthcare, but for the Imaging business, of course you have to realize that we should include for a good view the service part, so that comes a long way. Also on your question why the growths spur, well, there were somewhat of a muted growth in PCCI in Q4 that was only between 3% to 4%. So there is somewhat of a catch-up effect also. And besides that we think we have a great suite of very compelling products, being the leader particularly in [inaudible] globe that we are. Ben Uglow – Morgan Stanley: Sorry to interrupt. Is it far to think that you are seeing growth – I guess I interpreted from Frans’ answer that this was about IT and Clinical Informatics as opposed to simply saving more patient monitoring systems. Is that fair or not?

Well, I said that because it is, one, value proposition. So I was not specifically flagging that we sell more IT alone versus the boxes. I was trying to convey that it is the combination of both that makes it such an attractive proposition, so that the nurses have fewer things to do in order to help the patient and that the information is always at the fingertips, and that the patient can be followed at the emergency, ICU, and so on. So the whole thing is an integrated clinical solution rather than a box. Ben Uglow – Morgan Stanley: Okay, thank you.

All right. All right, then on your question on Lighting, well we have indeed seen raw materials fluctuate, so rare earth going up and down. There was a peak in the middle of last year then it came down a little bit and now it goes back up again. So it’s a very unstable situation, which we mitigate by having some term contracts that means that we are not seeing the immediate effect of those fluctuations back in our bottom line, whether up or down, and it becomes a bit more muted impact. Nevertheless, we are concerned about raw material availability and pricing, and it is not for nothing of course that three continents in the world, Europe, Japan and United States, all three have complained at WTO about the practices around rare earth. So it’s an area that we closely need to monitor. By the way we have launched some innovation projects in order to become less dependent on rare earth. We cannot eliminate it of course, but in our labs we have been able to find a way to significantly reduce the amount of rare earth that we need in order to make our products. So that in the midterm is good news, it will still take us to a couple of quarters before that comes to bear probably by 2013. But it is nice to see that when you put pressure on your organization, they come up with creative IDs. Ben Uglow – Morgan Stanley: Frans, thank you.

You’re welcome.

The next question comes from Ludovic Debailleux of Natixis Securities. Please go ahead, sir. Ludovic Debailleux – Natixis Securities: Good morning, gentlemen. A few questions please. First of all, you are targeting EUR400 million cost savings end of 2012 at Group level. Could you help us to quantify the effect for Q2, Q3 and Q4 of this year? That was question number one. Question number two, Innovation Group & Services, EBITA stand at plus EUR7 million, only minus EUR30 million excluding the capital gain. Even if you expect more charges to come in H2, do you confirm the minus EUR340 million for the full year you guided previously? And, maybe a last question on the free cash flow. What would have been the free cash flow in Q1 restated from the push-out effect from Q4 to Q1 on net scale? Thank you.

Okay. On your IG&S question, yes we reconfirmed the guidance. As I said, it was an amount of the HDC [ph] deal and the Senseo deal in the – on the HDC deal in the assets, because they also held at Group level, so that impact is favorable. Also, there is some seasonality in the number, so that explains the profit that we’ve actually shown in IG&S. So for the full year, I would reconfirm the guidance on the EUR340 million. Then on the EUR400 million cost savings where we had incremental savings in Q1 of EUR37 million and that was EUR25 million in Q4 last year. So the cumulative savings are now at EUR62 million in the first quarter and that provides we think for a good – for a good run rate. Of course, we’re coming to a point where we really need to push through on the design, we have everything in place and monitoring it very closely. So as we have said the cost savings program and the impact on the profit will be more at back half loaded. So EUR400 million on the cost savings, we have reconfirmed. Then the free cash flow push from Q1 and Q2, that effect in last year was about EUR300 million. We are otherwise still very pleased with the free cash flow performance that we have seen, because we did improve in our receivables position and overdues, inventories in Lighting and Lifestyle were well under control, Healthcare somewhat higher as explained earlier. And, of course, there is also somewhat of an effect of the fact that the month actually ended in the weekend, so this had two effect. People paid us somewhat later but we also paid people somewhat later due to that. And I think the net effect of that is about EUR100 million, EUR130 million plus impact. But again, we are very pleased with the free cash flow generation performance. Yes, so if you ask about the Healthcare push-out in the inventories, so why have inventories not gone down more in Healthcare? That’s because we are also gearing up for second half shipments of products maybe to China. And that is the explanation of the Healthcare increase. Of course, there is an undercurrent of making the supply chain a more efficient and we’re working hard to do that. But for now it is mainly – this increase is mainly related to production inventories for the new product introductions. Ludovic Debailleux – Natixis Securities: Thanks a lot.

The next question comes from Gaël De Bray of Societe Generale. Please go ahead, sir. Gael De Bray – Societe Generale: Hi, good morning, everyone. I was actually curious to know what was the negative EBITA contribution of Consumer Luminaires and Lumileds in Q1, and then how this contribution had developed over the past three to four quarters now. And I was also surprised to see restructuring charges in Lighting were almost three times lower than you initially guided for Q1, so if you could give us the reasons for that please, that would be great. And, maybe the second question on inventories, so I understand what happened in Q1, but still inventories were up roughly 100 bps and on a year-on-year basis in Q1. And that means you’re running well below the targeted 1% to 1.5% prediction for the full year. So do you consider yourself you are still on track for this specific target or have these things become really more difficult now?

Let me start with inventories and then I’ll ask Ron to comment on the EBITA effect of both Consumer Lum and Lumileds and restructuring in Lighting. So on inventories, I would say we are not yet on track. So a little bit more specifically, Lifestyle is progressing. In Lighting we still have a lot to do and Healthcare is behind especially on the Imaging side we’ve seen still high inventories. So the targets have all been deployed and programs are in place to redesign our supply chains and to get to a structure the lower level, but I would not yet call this as a done deal. Nevertheless we fully remain committed to improving by 2% to 3% over the two-year period. I look to my right here, Ron, on the other two points.

The Consumer Luminaires, yes, so the Consumer Luminaires impact on the full year Lighting for last year as I have explained at the time was about 230 basis points. So what we see on QonQ is just impact – is increase the Informatics tapering off, so we’re very pleased by that. We don’t give specific guidance for the adjusted EBITA on the Consumer Luminaires or on the Lumileds. Also Lumileds got slightly worse, but not to the tune that we have also guided, where it was about 250 basis points last year, impact on the full-year Lighting margin, and that is because we have seen some inventory correction at the customer. So we are working to bring both these businesses to a much higher level of performance and this is one of the stepping stones as we said on building our path to value in this second half of this year. On the restructuring charges, we guided for EUR60 million, we did EUR49 million actually, and there was a EUR25 million loss on the sale of assets. So a EUR21 million restructuring for that. So we don’t believe that we are way off of what we have said on the restructuring. Gael De Bray – Societe Generale: Okay, very clear. Thanks very much.

Thank you.

Thank you. The next question comes from Martin Prozesky from Sanford Bernstein. Please proceed with your question. Martin Prozesky – Sanford Bernstein: Good morning, everyone. Just two specific questions, please. On Healthcare and the guidance you gave on the US, we saw a growth of 5% in orders for the US, and you commented on the uncertainty given the challenges to healthcare reform. Can you give us a bit more color on how you look at the market over the coming two quarters? Do you see a high-level of uncertainty of what you’re hearing from your key clients there? How do they think the healthcare reform is likely to pan out talking of what other kind of the boundaries kind of around the outcomes? And then on Lighting, in terms of Lumiled external sales, you mentioned again that the external sales were down quite significantly, because of inventory corrections. How should we think about kind of external sales from Lumileds kind of over the next year?

All right, Martin thanks for that. Near-term the Healthcare outlook in the USA actually looks strong and we have the momentum both in terms of competitive products and order intake to show for that. The caution is more on what would happen towards the end of the year we cannot totally oversee at the impact of the new exercise tax coming in. And in that sense, 2013 is a little bit more uncertain, but near term we expect the train to plough – to plough through. With regard to Lumileds, we make – of course we talk about external sales which already implies that the internal sales also exist which we don’t separately show or convey. But we see strong momentum of our LED business and Lumileds has a big part to play in that in all three types of businesses, automotive, LEDs, into the lamps and also into the Luminaires. So significant portion of the Lumileds output goes to our internal customers. The external side, we have been working historically one distribution partner and some of the customers the larger ones we deal with directly. You may recall from past commentary that we used to sell also into the display market and not just the general illumination market. The display market is under a lot of pressure. This is, for example, as backlight in TV. Here is where there is a lot of price competition and we have lost a customer. The general illumination market, the lamps market in the external market is not yet so big. Most of the big lamp makers in the world have their strategic relationships and we expect that only over time will the GI market for Lumileds open up in a broader shelf. So that will still take a little while. In the meantime Lumileds is working on its operational excellence programs. With the new management on board, we can see in many ways to improve margins. We have some exciting new products coming out in the LUXEON range that have better margins and that will contribute in the rest of the year to a better margin. Martin Prozesky – Sanford Bernstein: Thank you. Just a one quick follow-up. On Consumer Lifestyle, it seems like the growth geographies were quite weak in the quarter. I think you commented in one of your presentations that China, India did well, but does this mean some of the other geographies declined in some of the growth geographies in Consumer Lifestyle or is it a comp effect with the license numbers going out?

Yes. Well, actually all that effect is due to Lifestyle Entertainment. We flagged that. Those were double-digit decline and that applies across the world, most you have seen in the mature markets and in several of our growth markets, the audio/video component is also present so you see the same effect. So the strengths of the – what we called the growth business or the core businesses, oral care, personal care, domestic appliances across the world are doing well. Martin Prozesky – Sanford Bernstein: Okay, thank you.

Thank you. The next question comes from Olivier Esnou from Exane BNP Paribas. Please proceed with your question. Olivier Esnou – Exane BNP Paribas: Hello, good morning. Thank you for taking my question. So first one, on the restructuring charge, it seems you are reducing the charge quite a bit over the next three years by about EUR100 million. So in total you will be spending just about two-fold [Technical Difficulty]? You’re keeping the savings intact, so there must be something else much better than you were expecting. Can you please come back to that a little bit? Second question on the Healthcare business, the capitalization of development cost has increased quite a little bit. Is that part of Accelerate! or is that business growing through a new development program, meaning we have a new run rate here, and if you can maybe guide on that. And, last question, on the outlook for US Imaging, when I look at the slide you have actually increased the midterm outlook from low single digit to low-to-mid single digit, this is despite your cautionary comment about taxation and impact towards your end. So what is fundamentally in your view going better midterm this US Healthcare market? Thank you.

Okay. Let me start with the first one – the last one, outlook of the US Imaging. Actually we are not changing our tone in the way we talk about, it’s the same. Then, I’d like to ask Ron to take the other two.

So we indicated restructuring cost in the previous quarter for 2012 of EUR200 million, that is now down to EUR125 million. So that is because there are a number of people leaving that do not apply for benefit package and there are a number of other people that we are otherwise of course to taking out overhead. But as we’re still growing, a small part of that is reemployed in where it makes sense to drive growth. So that is giving us actually for this year a slightly higher already impact in the EBITA. So we are pleased by that. And, of course, as I earlier said we have reconfirmed the EUR400 million, our cost program is on track. Then, on your question on capitalizing for R&D and Healthcare, and we disclosed this. So it’s actually on page 82 of the IR deck. There you see it’s slightly higher than Q1 of last year. Remind that we have a number of ongoing development and new products on the plate. And also this is an amount that usually goes up and down depending on new product introduction schedules. So I would have to come back to you on the full-year number that we have seen to give more clarity and maybe we can come back to you on that a little later. Olivier Esnou – Exane BNP Paribas: Thank you. Just a follow-on please. So if I understand well the restructuring charge is lower for ‘12 and actually your guidance for ’13, just because people that you are planning to let go have left by themselves. And is there a specific division which is more involved than the others in that respect?

No. There is also, of course, an element. When we do this, we estimate restructuring cost and we certainly don’t want to be off. It doesn’t mean that we are really – major to the number we do an estimate that best the insides and the actual cost pan out lower. And as I said, the number of people don’t apply full benefits and to a smaller extent people find other employment in the company. Olivier Esnou – Exane BNP Paribas: Okay, thank you very much.

Thank you. The next question comes from Phil Wilson from Redburn. Please proceed with your question. Phil Wilson – Redburn: Good morning, everyone. It’s Phil Wilson from Redburn. Thank you for taking my question. With your Healthcare equipment organic order growth, you have reported plus 7% with an improvement, looking for the detail I think it’s change things to Europe for the year-on-year rate has improved from minus 14 to minus 1. So my question is around the sustainability of this improvement and the outlook for the European Healthcare equipment order. Is it a one-off or can you see from the customer tenders that Europe is in recovery despite austerity?

Well, that’s worth a question. We are generally cautious in our outlook for the reason that this is not exactly predictable and we know that austerity measures in Europe are still further rolled out and may affect the order intake of the quarters to come. So this is an uncertainty that we will have view it. When we talk about many, many moving parts in our journey to the midterm targets and this is certainly one of them. I cannot give you any further assurance at this time on how Europe will develop. Phil Rubin – Red Bands: Okay, thank you very much.

Thank you. The next question comes from William Mackie from Berenberg Bank. Please proceed with your question. William Mackie – Berenberg Bank: Yes, good morning. A couple of Lighting, please. Firstly, a few more months have passed by and the industry has developed further. Could you update us on your views regarding the strategic position of Lumileds within your Lighting portfolio? And then, secondly, within the Lighting portfolio again, how far down the path do you see yourself with regard to as you refer to it realigning the manufacturing base of the traditional lamps business. Is that a two to five-year journey or are we coming close to the end of that process by the end of this year? Thank you.

Yes, all right. First of all, the position of Lumileds, I know that everybody is pushing us to make strong statements about it, whereas we kind of repeatedly say that for two reasons we want to be in the LED business. First of all, there is a lot of innovation going on between the packaged LED and the application side. This applies to automotive, it applies to lamps and to luminaires. We believe that we are well placed to take a benefit from that innovation and generate intellectual property on it, but also the trade secrets give us an edge and we don’t want that to be passed on to competitors. The second reason is, is that, we are not totally clear on how the supply market will pan out for the LEDs. Today, there is a fragment in market with many players, but our expectation is, is that that market will become far more concentrated. And as it becomes concentrated, Philips as the largest lighting player in the world cannot become dependent on for example assumption for its source of LEDs. So having an internal supply source for those reasons is important. And, of course, we monitor very carefully whether we are right in these assumptions and also whether we are the rightful owner. But for now we believe we are and we are working hard to improve the operational results of Lumileds. Then, your question on the industrial footprint, we are working hard to take care of that. Two years ago – four years ago in 2008, Philips Lighting had approximately – okay, let me rephrase that, I’m getting some advice from my colleagues here. If we put an index on the amount of factories and if you look at the developments since 2008, so let’s put the index on our 104 years ago in 2008, then today we are around at 70, so we have taken about a 30% of the industrial footprint down. And our forecast is that we will take that further down to between 40% and 50% by the year 2015. Of course, this depends on how fast the market shifts to LED or in other words how long the golden tail will be the cash cow of the predicted will be. So basically we would be halfway down by 2013, 2014. So there are still bits to go. And this factory adjustment applies for mostly to the lamps business, but also to a degree to some of the factories in the luminaires space where we are shifting factories from the Western side of Europe. For example, to Eastern Europe. William Mackie – Berenberg Bank: Okay, thank you very much.

Thank you. The last question comes from Andrew Carter from RBC. Please proceed with your question. Andrew Carter – Royal Bank of Canada: Thanks, good morning. And most of my questions have been answered, but I wondered if I can just ask one more on the restructuring program. One of the slides in the pack, I think it’s slide 35 shows the actual headcount reduction and talks about 4,500 of headcount reduction. I wondered if you could just sort of mentioned it’s not 4,500 to be completed by the end of 2012. And then also just in terms of the progress that you’ve actually made, it appears that the number of people leaving the company was quite a bit lower in the more recent quarter compared to the previous one and I was just wondering does that actually mean that the cumulative growth savings that we should expect in the Q2 coming up, is that going to be a sort of a relative small increase in cost savings or is that not the way to think about it.

So the – first of all, the 4,500 people is by 2014. So that is about 15% of the workforce that it pertains to. If you look at the 1,190 that was the people who really have left, so there is no – there are few who found new employment maybe for good reasons, but the vast majority of course of this people have left. So the restructuring cost we have said are somewhat lower. So at the lower run rate in the restructuring cost – and it means the EBITA impact for the full year will be somewhat higher. And as I said earlier, the main impact will be the second half of the year. Does that answer your question? Andrew Carter – Royal Bank of Canada: Yes. But if I could just ask just a bit more though just in terms of the smaller number of people leaving in this quarter has just been completed, does that mean that we will get a similar level of sort of increase in the growth savings in this next quarter or is it not going to be such an improvement?

Well, this number goes a little bit up and down in the quarters. These are discretionary decisions that we take aligned with the workers’ council application that we do and the decision that come from that. So I will just that for now we are encouraged by what we see. We are on track with the cost saving. I think that’s a good and heartening news, EUR62 million cumulative savings. In general, I mean you have heard us talk about the fact that we expect the underlying operating margins off the three sectors to improve in the second half of the year. We say that for a reason. Also some of the improvements are slated to show up in the bottom-line in that timeframe. So perhaps that also helps you a little bit. Andrew Carter – Royal Bank of Canada: Thank you very much.

All right. Ron.

You were going to wrap up, right?

Yes.

So just two things. Earlier I was asked on the IG&S cost and I said EUR340 million, as per earlier guidance I just want everybody to bear in mind in that number was EUR70 million for restructuring. That is one. And second is – and the second is that the capital markets day for Healthcare will be on May 9 and 10 in Boston. And, of course, we look very much forward to welcoming you there.

Yes. And Deborah DiSanzo will be there to welcome you as well. Well, let me wrap it up, and so thank you for joining. Let me reiterate that we seek Q1 improvement as a first step on the journey to our midterm targets. The unlock potential Philips is much larger, we have a lot of work still to do, but we are confident that we can do that. Philips is repositioning itself into attractive market of healthcare, energy, efficient lighting, consumer health and wellbeing. So we are in an industrial goods company and we compete on the basis of innovation and customer intimacy. And then the closing the TV deal was something we promised and we delivered on, we feel good about that. And we will with the same vigor and conviction work on all the other issues that we still have to address and solve. We know that – they are many things to do, but the team really is now completed to top and we feel that we are getting into a flow to get it all done. So thank you for being patient with us and we hope to be able to talk to you soon. Thanks very much.

This concludes the Royal Philips Electronics first quarter results 2012 conference call on Monday, 23rd of April, 2012. Thank you for participating. You may now disconnect.